Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: a randomized controlled

Sin T Lo1, Elbrich P C Siemensma, Dederieke A M Festen

  • 1Dutch Growth Research Foundation, Westzeedijk 106, 3016 AH, Rotterdam, The Netherlands, s.lo@kindengroei.nl.

Insights

Growth hormone (GH) treatment did not significantly alter behavioral problems in children with Prader-Willi syndrome (PWS). Social difficulties were most prominent, but overall behavior remained consistent with peers with intellectual disabilities.

Area of Science:

  • Pediatric Endocrinology
  • Developmental Psychology
  • Genetics

Background:

  • Prader-Willi syndrome (PWS) is a complex genetic disorder impacting development and behavior.
  • Limited data exists on behavioral issues in PWS and the efficacy of growth hormone (GH) treatment.
  • Parental reports suggest potential behavioral improvements with GH, warranting further investigation.

Purpose of the Study:

  • To investigate the long-term effects of GH treatment on behavior in children with PWS.
  • To compare behavioral profiles of children with PWS to peers with similar intellectual disabilities.
  • To identify specific behavioral challenges within the PWS population.

Main Methods:

  • A 2-year randomized controlled trial (RCT) followed by 8 years of longitudinal GH treatment in 42 pre-pubertal children with PWS.
  • Behavioral assessments using the Developmental Behavior Checklist (DBC) and the Children's Social Behavior Questionnaire (CSBQ).
  • Comparison of PWS behavioral scores against a reference population with comparable intellectual disability.

Main Results:

  • Children with PWS exhibited problem behavior comparable to peers with intellectual disabilities.
  • Social disabilities were significantly more pronounced in PWS children compared to their overall DBC scores.
  • GH treatment showed no significant positive or negative impact on behavioral problems during the study period.
  • Lower IQ correlated with increased self-absorbed and communication problems.

Conclusions:

  • Behavioral problems in children with PWS are similar to those in children with comparable intellectual disabilities.
  • Social interaction deficits represent the most significant behavioral challenge in PWS.
  • Long-term GH treatment does not appear to modify behavioral issues in children with PWS, contrary to some parental expectations.

Related Concept Videos

Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
2.1K
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
23.1K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Major Hormones and Their Functions01:27

Major Hormones and Their Functions

Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
3.6K